Intermittent preventive treatment of infants with mefloquine reduces risk of clinical malaria in areas of moderate malaria transmission and high resistance to sulphadoxine - Pyrimethamine, but safety and tolerability issues need consideration

Evidence-Based Medicine

Volumn 15, Issue 3, 2010, Pages 71-72

  McGready, Rose ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ARTEMISININ; CHLORPROGUANIL PLUS DAPSONE; DIPHTHERIA PERTUSSIS POLIOMYELITIS TETANUS VACCINE; MEFLOQUINE; PIPERAQUINE; PLACEBO; PYRIMETHAMINE; SULFADOXINE;

ANEMIA; ANTIMALARIAL DRUG RESISTANCE; AXILLA TEMPERATURE; BED NET; CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG INTERMITTENT THERAPY; DRUG SAFETY; DRUG TOLERABILITY; FEVER; GABON; HOSPITAL ADMISSION; HUMAN; IMMUNIZATION; INFANT; INFECTION RISK; MALARIA; MEASLES; MORTALITY; NOTE; PARASITEMIA; PROPHYLAXIS; RISK REDUCTION; TANZANIA; TREATMENT FAILURE; VOMITING;

EID: 77953799477     PISSN: 13565524     EISSN: 14736810     Source Type: Journal    
DOI: 10.1136/ebm1039     Document Type: Note

References (18)

1. Checchi F, Piola P, Kosack C, et al. Antimalarial efficacy of sulfadoxine-pyrimethamine, amodiaquine and a combination of chloroquine plus sulfadoxine-pyrimethamine in Bundi Bugyo, western Uganda. Trop Med Int Health 2004;9:445-50.
2. Tagbor H, Bruce J, Browne E, et al. Efficacy, safety, and tolerability of amodiaquine plus sulphadoxine-pyrimethamine used alone or in combination for malaria treatment in pregnancy: a randomised trial. Lancet 2006;368:1349-56. (Pubitemid 44528748)
3. Tinto H, Ouédraogo JB, Zongo I, et al. Sulfadoxinepyrimethamine efficacy and selection of Plasmodium falciparum DHFR mutations in Burkina Faso before its introduction as intermittent preventive treatment for pregnant women. Am J Trop Med Hyg 2007;76:608-13. (Pubitemid 351627694)
4. Aponte JJ, Schellenberg D, Egan A, et al. Efficacy and safety of intermittent preventive treatment with sulfadoxinepyrimethamine for malaria in African infants: a pooled analysis of six randomised, placebo-controlled trials. Lancet 2009;374:1533-42.
5. Evans SJ, Waller PC. Neurological, cardiovascular and metabolic effects of mefloquine in healthy volunteers: a double-blind, placebo-controlled trial. Br J Clin Pharmacol 1997;43:665.
6. Luxemburger C, Price RN, Nosten F, et al. Mefloquine in infants and young children. Ann Trop Paediatr 1996;16:281-6.
7. Slutsker LM, Khoromana CO, Payne D, et al. Mefloquine therapy for Plasmodium falciparum malaria in children under 5 years of age in Malawi: in vivo/in vitro efficacy and correlation of drug concentration with parasitological outcome. Bull World Health Organ 1990;68:53-9. (Pubitemid 20153770)
8. Ashley E, McGready R, Singhasivanon P, et al. In vivo sensitivity monitoring of mefloquine monotherapy and artesunate-mefloquine combinations for the treatment of uncomplicated falciparum malaria in Thailand in 2003. Trop Med Int Health 2006;11:1898-9; author reply 1899.
9. Barnes KI, Durrheim DN, Little F, et al. Effect of artemetherlumefantrine policy and improved vector control on malaria burden in KwaZulu-Natal, South Africa. PLoS Med 2005;2:e330.
10. Nosten F, van Vugt M, Price R, et al. Effects of artesunatemefloquine combination on incidence of Plasmodium falciparum malaria and mefloquine resistance in western Thailand: a prospective study. Lancet 2000;356:297-302. (Pubitemid 30459588)
11. White NJ. How antimalarial drug resistance affects post-treatment prophylaxis. Malar J 2008;7:9.
12. WHO. Report of the Technical Consultation on Intermittent Preventive Treatment in Infants (IPTi), Technical Expert Group on Preventive Chemotherapy. Geneva: WHO, 2009.
13. Gesase S, Gosling RD, Hashim R, et al. High resistance of Plasmodium falciparum to sulphadoxine/pyrimethamine in northern Tanzania and the emergence of dhps resistance mutation at Codon 581. PLoS ONE 2009;4:e4569.
14. Hutton G, Schellenberg D, Tediosi F, et al. Cost-effectiveness of malaria intermittent preventive treatment in infants (IPTi) in Mozambique and the United Republic of Tanzania. Bull World Health Organ 2009;87:123-9.
15. IOM. Committee on the Perspectives on the Role of Intermittent Preventive Treatment for Malaria in Infants. Assessment of the Role of Intermittent Preventive Treatment for Malaria in Infants: letter report. Washington, District of Columbia, USA: Institute of Medicine, 2008. http://www.nap.edu/cataolg.php? record-id-12180 (Accessed 10 January 2010).
16. WHO IPTi Technical Expert Group. Intermittent preventive antimalarial treatment in infancy. Lancet 2008;372:1383-4.
17. Bill and Melinda Gates Foundation. New Prevention Strategies: $28 Million for Research on Intermittent Preventive Treatment in Infants (IPTi). IPTi Consortium, 2004. http:// www.gatesfoundation.org/press-releases/Pages/ malariaresearch-grants-030921.aspx (Accessed 15 January 2010).
18. Cissé B, Sokhna C, Boulanger D, et al. Seasonal intermittent preventive treatment with artesunate and sulfadoxinepyrimethamine for prevention of malaria in Senegalese children: a randomised, placebo-controlled, double-blind trial. Lancet 2006;367:659-67.